CLINICAL STUDY

Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance

Maria P Matta, Elisabeth Couture, Laurent Cazals, Delphine Vezzosi, Antoine Bennet and Philippe Caron
Department of Endocrinology and Metabolic Diseases, CHU Larrey, 31059 Toulouse, France and 1Department of Diabetes and Metabolism, CHU Rangueil, 31059 Toulouse, France

(Correspondence should be addressed to P Caron who is now at Department of Endocrinology, CHU Larrey, 24 Chemin de Pourvouville, TSA 30030, 31059 Toulouse Cedex 9, France; Email: caron.p@chu-toulouse.fr)

Abstract

Introduction: Acromegaly, a chronic disease caused by GH/IGF-I excess, has a major impact on quality of life (QoL).
Objective: To evaluate QoL of acromegalic patients in relation to control status of the disease.
Design and methods: Single center observational study including 93 patients with acromegaly recruited to complete QoL questionnaire (AcroQol). QoL was evaluated at least 3 months after surgery and/or medical treatment. Patients were divided into two groups: controlled (I) and uncontrolled (II) according to the latest consensus acromegaly ‘control’ criteria and further subdivided into four subgroups according to the previous pituitary adenoma surgery (Ib and IIb) or without surgery (Ia and IIa).
Results: Mean GH (0.81 ± 0.47 ng/ml) and IGF-I (195 ± 71 ng/ml) values in group I were significantly lower than in group II (GH, 7.01 ± 12.05 ng/ml and IGF-I, 513 ± 316 ng/ml; P < 0.001). There was no difference in total AcroQol score, physical, or psychological scales between groups I and II. However, when adjusted to age and disease duration since diagnosis, patients of group I (63 ± 20%) showed an improved psychological subscale appearance than those of group II (58 ± 17%; P = 0.035). In group II, IGF-I level was lower after surgery (IIa = 588 ± 353, IIb = 410 ± 225 ng/ml; P < 0.038), and psychological subscale appearance was significantly better in subgroup IIb (64.9 ± 18.1%) than in subgroup Ia who had medical treatment (53.9 ± 14.3%; P = 0.009).
Conclusion: QoL is severely impaired in acromegalic patients. Control of GH/IGF-I excess by surgery or medical treatment seems to have a positive impact on psychological subscale appearance.

European Journal of Endocrinology 158 305–310

Introduction

Acromegaly is an insidious chronic disease caused by hypersecretion of growth hormone (GH) and insulin-like growth factor-I (IGF-I), and is associated with an increased morbidity and mortality, mainly through cardiovascular, metabolic, and neoplastic complications. Increased life expectancy is directly related to the control of the disease. Current therapeutic armamentarium including transsphenoidal surgery, radiotherapy, and medical treatment with dopamine agonists, somatostatin analogs, and/or GH receptor antagonist drug (pegvisomant) induce biochemical cure in almost all patients with acromegaly (1, 2) according to consensus criteria (3). Previous reports demonstrated the efficiency of these treatments in reversing the mortality rate of patients to that of age-matched healthy subjects (4, 5). However, whether control of the disease improves quality of life (QoL) gives rise to controversy (6).

The aim of the present clinical study was to assess QoL in relation to control status of the disease in a large cohort of treated acromegalic patients using the French validated version of the AcroQol questionnaire.

Patients and methods

Ninety-three acromegalic patients who attended our department between July 2004 and September 2006 were asked to complete the AcroQol French version questionnaire.

Patients were divided into two groups: controlled (I) and uncontrolled (II) groups according to remission criteria (nadir serum GH concentration after oral glucose tolerance test (OGGT) < 1 ng/dl or mean GH level < 2.5 ng/ml and age- and gender-specific IGF-I normal concentration).

Characteristics of patients, such as age, gender, duration of the disease since the diagnosis of acromegaly, previous and current treatment of acromegaly, and related co-morbidities were recorded by chart review. GH and IGF-I levels were measured at the time of completing the QoL questionnaire.
GH assays were performed using a chemiluminescence technique (Nichols Institute diagnostics, San Clemente, CA, USA). The detection limit is 0.02 µg/l and the intra-and inter-assay coefficient of variation (CV)s are 3.7 and 6.2% respectively. IGF-I assay was performed using a chemiluminescence technique (Nichols Institute Diagnostics). The detection limit is 6 µg/l and the intra- and inter-assay CVs are 5.2 and 5.7% respectively.

The study protocol was approved by the medical ethic committee and all subjects gave their written informed consent.

The acromegaly QoL questionnaire (AcroQol), originally developed in Spanish (7, 8) and was designed to assess QoL in patients with acromegaly. The questionnaire comprises 22 items covering physical and psychological aspects of acromegaly. The latter subdivided into ‘appearance’ and ‘personal relation’ subscales.

Each question has five possible answers scoring 1–5. Results are quoted as a percentage with a minimal score of 0% and a maximal score of 100% equating worse and best QoL respectively.

Statistical analysis

Stata statistical software (StataCorp., 4905, Lakeway Drive, College Station, TX 77845, USA) was used to perform data analysis. Data were expressed as mean ± s.d. unless otherwise mentioned. Comparison between groups was done using uni- and multivariate regression analyses. $P_X$ was calculated by multivariate regression analysis after adjustment for age and disease duration. In bivariate analysis, χ² test or Fisher’s exact test was used when appropriate to compare the distribution of qualitative variables between groups. Means of quantitative variables were compared using Student’s t-test. Spearman’s rank-order correlation was used for non-parametric data. A P value <0.05 was considered statistically significant.

Results

Ninety-three acromegalic patients (55 women/38 men; 26–85 years of age) with a mean time since acromegaly diagnosis of 9.5 years (0–38 years) completed the French version of QoL questionnaire (AcroQol). Two groups were identified: controlled (I, n=36) and uncontrolled (II, n=57) according to ‘control’ criteria. Only two patients were treated with pegvisomant, for those patients, control of the disease was defined by normal age- and sex-adjusted IGF-I level.

During treatment, 38 patients underwent pituitary surgery, 13 had radiotherapy, and 11 had both surgery and radiotherapy. Treatment with long-acting somatostatin analogs (slow-release lanreotide, somatuline autogel, sandostatin long-acting release (LAR)) were given to 71 patients and similar in 29 patients (81%) in group I and 42 patients (74%) in group II. Overall mean SMS analog treatment was 6.58 years (0–21.1 years). Six patients in the uncontrolled group did not receive any treatment for acromegaly as they were evaluated at the time of diagnosis, whereas two patients in the controlled group only dopamine agonist treatment.

Associated hypopituitarism was treated with hormonal replacement therapy in 19 patients (Table 1).

Mean GH (0.81 ± 0.47 ng/ml) and IGF-I (195 ± 71 ng/ml) values in group I were significantly lower than in group II (GH, 7.01 ± 12.05 ng/ml and IGF-I, 513 ± 316 ng/ml; P <0.001). Obstructive sleep apnea syndrome was more frequent in group II (44%) than in group I (17%; P <0.007). Joint-related complaints were found in 39% of patients in group I and 46% of

<table>
<thead>
<tr>
<th>Variable (group)</th>
<th>Controlled (I)</th>
<th>Uncontrolled (II)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>36</td>
<td>57</td>
<td></td>
</tr>
<tr>
<td>Age (mean, years)</td>
<td>58.4</td>
<td>52.0</td>
<td>0.0219</td>
</tr>
<tr>
<td>Male/female</td>
<td>7 males/29 females (19.4%)</td>
<td>31 males/26 females (54.3%)</td>
<td>0.001</td>
</tr>
<tr>
<td>Years from diagnosis (mean)</td>
<td>10.5</td>
<td>8.8</td>
<td>0.4133</td>
</tr>
<tr>
<td>Mean GH (ng/ml)</td>
<td>0.81 ± 0.47</td>
<td>7.01 ± 12.05</td>
<td>0.0032</td>
</tr>
<tr>
<td>Mean IGF-I (ng/ml)</td>
<td>196 ± 71</td>
<td>514 ± 316</td>
<td>0.00001</td>
</tr>
<tr>
<td>Treatment of acromegaly</td>
<td>Previous surgery</td>
<td>15</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>Surgery + radiotherapy</td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>Surgery + SMS</td>
<td>10</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>SMS alone without surgery</td>
<td>19</td>
<td>26</td>
</tr>
<tr>
<td></td>
<td>Dopamine agonists</td>
<td>9</td>
<td>24</td>
</tr>
<tr>
<td></td>
<td>Pegvisomant</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Associated complications</td>
<td>Hypertension</td>
<td>15 (41.6%)</td>
<td>19 (33.3%)</td>
</tr>
<tr>
<td></td>
<td>Diabetes</td>
<td>4 (11.1%)</td>
<td>15 (26.3%)</td>
</tr>
<tr>
<td></td>
<td>Sleep apnea syndrome</td>
<td>6 (16.6%)</td>
<td>25 (43.8%)</td>
</tr>
<tr>
<td></td>
<td>Joint-related complaints</td>
<td>14 (38.8%)</td>
<td>26 (45.6%)</td>
</tr>
<tr>
<td></td>
<td>Treated hypopituitarism</td>
<td>7 (19%)</td>
<td>12 (21%)</td>
</tr>
</tbody>
</table>
In this cohort of treated patients with acromegaly, the total score of AcroQol questionnaire is 59 ± 18%...
acromegaly (15, 16). Sleep apnea syndrome affects with epidemiological morbidity studies in active
uncontrolled group showed significantly lower HR-QoL than the
controlled group using the same criteria as the present
study for defining remission status of the disease (11).
Another study (12) demonstrated no correlation
between biochemical control and any measure of QoL,
using AcroQol and several generic well-being tools such
as psychological well-being schedule (PGWBS) and
signs and symptoms score (SSS). In our cohort of
treated acromegalic patients, we observed a weak and
inverse correlation between psychological subscale
appearance and IGF-I value. Recently, a negative
 correlation was also observed between changes in
IGF-I levels and overall AcroQol score and its physical,
psychological and appearance subdomains in treated
acromegalic patients (13). Moreover, in a large
European study including 817 patients with acrome-
galy treated with long-acting octreotide formulation
(sandostatin LAR) for at least 3 months, an inverse
correlation was observed between global AcroQol score,
GH \( (r = -0.076, P=0.03) \) and IGF-I \( (r = -0.071,\)
\( P=0.045 \) \) values (14), significant result due to the
large number of patients included. Therefore, control of
GH/IGF-I excess has an impact on QoL of acromegalic
patients mainly through the most affected psychological
subscale appearance.

In treated and well-controlled patients, persisting
co-morbidities may have contributed to reduced QoL,
as previously reported (15). Hypertension occurred in
33–41% of our patients, diabetes mellitus was encoun-
tered in 11–26%, whereas the most prevalent morbidity
was joint-related complaints occurring in 39–45%.
The prevalence of these co-morbidities is comparable
with epidemiological morbidity studies in active
acromegaly (15, 16). Sleep apnea syndrome affects
60–70% of acromegalic patients (17). In our cohort,
43.8% of the uncontrolled group suffered from sleep
apnea syndrome versus 16.6% of the controlled group
\( (P<0.007) \). The lower prevalence of SAS in controlled
group was expected as part of beneficial mediated effect
of lower IGF-I on upper airway soft tissue (18, 19). In
the present study, controlled group of acromegalic
patients showed a significantly better subscale psycho-
logical appearance than those of uncontrolled group
independent of age and disease duration. This finding
might be related to lesser incidence of sleep apnea
syndrome or ‘snoring’ representing one of the seven
items of psychological subscale appearance.

Numerous studies have documented that controlling
GH/IGF-I excess either by surgery or medical treatment
ameliorates biochemical profile and reduces morbidity
and mortality (20, 21). However, whether these
improvements translate into positive impact on
health-related QoL remains controversial. Conflicting
data previously reported, showed that either a negative,
neutral, or even positive influence on QoL of successfully
treated acromegalic patients (6, 11, 12). Furthermore,
patients with uncontrolled disease who have undergone
pituitary surgery showed better psychological subscale
appearance than those treated medically. Despite the
uncontrolled GH/IGF-I hypersecretion, patients who
underwent surgery had significantly lower IGF-I level
thus lower disease activity which could explain the
positive impact on their psychological subscale appear-
ance score. According to previous studies, reduction of
tumor mass by surgery enhances the response to
somatostatin analogs and increases the likelihood of
achieving biochemical disease control (22, 23). There-
fore, in such uncontrolled patients, surgical debulking
may increase hormonal control, reduce morbidity, and
ameliorate QoL. It is noteworthy that the positive impact
of surgery in the uncontrolled group is higher than
would have been expected given that patients who had
undergone surgery presented a higher prevalence of
hypopituitarism than patients treated with somato-
statin analogs alone. It seems that the increased
frequency of hypopituitarism after surgery in controlled
and uncontrolled groups did not significantly affect
the QoL of these patients. This might be explained by
the fact that patients with hypopituitarism were on
hormonal replacement therapy. Moreover, none had GH

\[
\begin{array}{llllll}
\text{Table 4 Acromegaly quality of life (AcroQol) scores in four subgroups of acromegalic patients.} \\
\hline
\text{Variables} & \multicolumn{2}{c}{\text{Controlled (I)}} & \multicolumn{2}{c}{\text{Uncontrolled (II)}} \\
\hline
\multicolumn{1}{c}{} & \text{Surgery (-) (Ia)} & \text{Surgery (+) (Ib)} & \text{Surgery (-) (Ia)} & \text{Surgery (+) (Ib)} \\
\text{N} & 19 & 15 & 26 & 23 \\
\text{Total score} & 59.7 \pm 21.5 & 60.8 \pm 12.1 & 57.9 \pm 16.9 & 60.4 \pm 21.5 \\
\text{Scale 1} & 63.9 \pm 17.3 & 65.9 \pm 17.9 & 65.1 \pm 17.9 & 64.9 \pm 19.3 \\
\text{Scale 2} & 70.5 \pm 18.7 & 70.3 \pm 11.6 & 67.5 \pm 13.9 & 71 \pm 18.3 \\
\text{Scale 2–1} & 63.7 \pm 22 & 72.4 \pm 15.6 & 53.9 \pm 14.3 & 64.9 \pm 18.1 \\
\text{Scale 2–2} & 77.5 \pm 16.8 & 78.7 \pm 12.3 & 78.6 \pm 14.8 & 77.0 \pm 20.3 \\
\hline
\end{array}
\]

Comparisons between groups using uni- and multivariate regression analyses. \( P \): \( P \) values after adjustment to age and disease duration. Scale 1, physical scale; scale 2, psychological scale; scale 2–1, psychological subscale ‘appearance’; and scale 2–2, psychological subscale ‘personal relationships’.

www.eje-online.org
deficiency which is known to have the most negative impact on QoL in hypopituitarism and thirdly, AcroQol questionnaire does not cover areas of life affected by pituitary hormone deficiency and may not be a sensitive tool in the latter field (24, 25).

In the two groups (groups I and II), the majority of patients were treated with a somatostatin analog. Long-acting formulations of somatostatin analogs (octreotide LAR, slow-release lanreotide, somatuline autogel) are well tolerated and effective with regard to suppression of GH secretion and tumor shrinkage (26, 27). All acromegalic patients treated by long-acting forms of somatostatin analogs had monthly injections done by nurses of their neighborhood. Recently, a cross-sectional study including 52 patients with treated acromegaly showed no difference in the AcroQol scores between controlled and uncontrolled groups (28). However, in the biochemically controlled group, patients treated with i.m. lanreotide injections had significantly worse QoL in comparison with those without lanreotide treatment. The negative impact of lanreotide treatment should be interpreted with caution. The major limitation of this study is the small sample size. Moreover, GH level was significantly higher in controlled patients who received lanreotide treatment than those with no medical treatment. This finding suggests that the lower the disease activity the better the QoL. Furthermore, i.m. injections of slow-release lanreotide administered every 2 weeks in a hospital setting might generate psychological distress and less of a sense of well-being in patients with controlled disease. However, it has recently been reported that training patients self- or partner administration of the new lanreotide autogel formulation may confer advantages in terms of clinic visits, independence and patient’s well-being without compromising control of GH/IGF-I excess (29). Further investigations are mandatory to tailor the therapy based on a patient’s individual requirements taking into consideration not only control of GH/IGF-I excess but also physical and psychological functions in patients with acromegaly.

Acknowledgements

The authors confirm that there is no source of funding relevant to the research reported in this manuscript and declare that there is no conflict of interest that would prejudice their impartiality.

References


Received 8 December 2007
Accepted 14 December 2007